Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Search research articles

Related Experiment Videos

Zelmac (Novartis AG).

¹Norman Consulting, 18 Pink Lane, Burnham, Buckinghamshire, SL1 8JW, UK. pn29@student.open.ac.uk

Idrugs : the Investigational Drugs Journal

|September 15, 2005

Summary

This summary is machine-generated.

Novartis is developing Zelmac (SDZ-HTF-919), a 5-HT4 receptor partial agonist, for gastric motility disorders and irritable bowel syndrome (IBS). This drug is currently in phase III clinical trials, with projected sales of 240 million Swiss Francs in 2001.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Working with Insulin, Carbohydrates, Ketones and Exercise to Manage Diabetes (WICKED): evaluation of a self-management course for young people with Type 1 diabetes.

Diabetic medicine : a journal of the British Diabetic Association·2019

Same author

Experiences of self-management among young adults with Type 1 diabetes in the context of a structured education programme: a qualitative study.

Diabetic medicine : a journal of the British Diabetic Association·2018

Same author

Optical absorption and magnetic circular dichroism spectra of thiouracils: a quantum mechanical study in solution.

Photochemical & photobiological sciences : Official journal of the European Photochemistry Association and the European Society for Photobiology·2017

Same author

Geographic variation in the treatment of non-ST-segment myocardial infarction in the English National Health Service: a cohort study.

BMJ open·2016

Same author

The importance of mindfulness in psychosocial distress and quality of life in dermatology patients.

The British journal of dermatology·2016

Same author

Patient and hospital determinants of primary percutaneous coronary intervention in England, 2003-2013.

Heart (British Cardiac Society)·2016

Same journal

Filibuvir, a non-nucleoside NS5B polymerase inhibitor for the potential oral treatment of chronic HCV infection.

IDrugs : the investigational drugs journal·2010

Same journal

Remimazolam, a short-acting GABA(A) receptor agonist for intravenous sedation and/or anesthesia in day-case surgical and non-surgical procedures.

IDrugs : the investigational drugs journal·2010

Same journal

LX-1031, a tryptophan 5-hydroxylase inhibitor that reduces 5-HT levels for the potential treatment of irritable bowel syndrome.

IDrugs : the investigational drugs journal·2010

Same journal

Dexpramipexole, the R(+) enantiomer of pramipexole, for the potential treatment of amyotrophic lateral sclerosis.

IDrugs : the investigational drugs journal·2010

Same journal

Lu-AA21004, a multimodal serotonergic agent, for the potential treatment of depression and anxiety.

IDrugs : the investigational drugs journal·2010

Same journal

Florbetapir (18F), a PET imaging agent that binds to amyloid plaques for the potential detection of Alzheimer's disease.

IDrugs : the investigational drugs journal·2010

See all related articles

Area of Science:

Gastroenterology
Pharmacology
Clinical Trials

Background:

Gastric motility disorders and irritable bowel syndrome (IBS) are common gastrointestinal conditions.
Current treatments for these conditions have limitations.
5-HT4 receptor agonists represent a potential therapeutic target.

Purpose of the Study:

To evaluate the efficacy and safety of Zelmac (SDZ-HTF-919) in patients with gastric motility disorders and IBS.
To assess Zelmac as a 5-HT4 receptor partial agonist for gastrointestinal indications.

Main Methods:

Phase III clinical trials are underway to assess Zelmac.
The study involves patients diagnosed with gastric motility disorders and IBS.
Pharmacological action is as a 5-HT4 receptor partial agonist.

Related Experiment Videos

Main Results:

Zelmac is in phase III clinical trials, indicating promising early-stage results.
The drug targets 5-HT4 receptors, suggesting a specific mechanism of action.
Projected sales of 240 million Swiss Francs by 2001 highlight commercial expectations.

Conclusions:

Zelmac shows potential as a novel treatment for gastric motility disorders and IBS.
Further clinical trial data will confirm its therapeutic value and safety profile.
The drug's development signifies advancements in 5-HT4 receptor agonist research.